Risk of developing chemotherapy-induced febrile neutropenia (FN) depends on patient-, treatment-, and disease-related characteristics. 1 In our prior investigation, several chronic comorbidities were associated with significantly increased FN
Search Results
A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora
Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao
Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman
Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood
CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
Sriman Swarup, Anita Sultan, Somedeb Ball, Francis Mogollon-Duffo, Nimesh Adhikari, Yin M. Myat, Myo H. Zaw, Catherine Jones, and Kyaw Z. Thein
) Conclusion: CDK 4/6 inhibitors–based regimen significantly contributed to all hematologic toxicities as well as febrile neutropenia. The improved efficacy outcomes and manageable toxicities with CDK 4/6 inhibitors are observed with proper supportive care and
Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence
Gary H. Lyman
Dr. Lyman has received research grant support from Amgen and GlaxoSmithKline and is on the speakers' bureau of Amgen and OrthoBiotech. References 1 Lyman GH Kuderer NM . Epidemiology of febrile neutropenia . Support Cancer Ther
Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy
Gary H. Lyman and Jessica Malone Kleiner
– 454 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymph 2003 ; 44 : 2069 – 2076 . 3. Lyman GH . Guidelines of
BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy
Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger
Background Prophylaxis with the recombinant human granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim prevents chemotherapy-induced neutropenia; reduces febrile neutropenia (FN) risk and infection-related and early
CLO23-048: Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations
Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, and Rajesh Thirumaran
Background: Febrile neutropenia (FN) being a life-threatening complication of chemotherapeutic drugs, demands extraordinary and distinct care than non neutropenic and septic patients. We used the National Inpatient Sample (NIS) database to
BPI20-011: Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens
Kimberly Rose Hedstrom, Margaret Rausa, Eric Gratias, and Stephen Hamilton
Background: The National Comprehensive Cancer Network (NCCN) establishes standard of care for patients receiving anticancer therapy, and classifies regimens based on febrile neutropenia (FN) and emesis risks. eviCore healthcare licenses NCCN
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018
Weijia Wang, Edward Li, Kim Campbell, and Ali McBride
Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer
